169 related articles for article (PubMed ID: 37548149)
1. Inactivated vaccine fueled adaptive immune responses to Omicron in 2-year COVID-19 convalescents.
Liu M; Zhang J; Li L; Tian J; Yang M; Shang B; Wang X; Li M; Li H; Yue C; Yao S; Lin Y; Guo Y; Zong K; Zhang D; Zhao Y; Cai K; Dong S; Xu S; Zhan J; Gao GF; Liu WJ
J Med Virol; 2023 Aug; 95(8):e28998. PubMed ID: 37548149
[TBL] [Abstract][Full Text] [Related]
2. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.
Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H
Front Immunol; 2023; 14():1170759. PubMed ID: 37180152
[TBL] [Abstract][Full Text] [Related]
4. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
5. One-Year Sustained Cellular and Humoral Immunities in Coronavirus Disease 2019 (COVID-19) Convalescents.
Zhang J; Lin H; Ye B; Zhao M; Zhan J; Dong S; Guo Y; Zhao Y; Li M; Liu S; Zhang H; Xiao W; Guo Y; Yue C; Zhang D; Yang M; Zhang J; Quan C; Shi W; Liu X; Liu P; Jiang Y; Wu G; Gao GF; Liu WJ
Clin Infect Dis; 2022 Aug; 75(1):e1072-e1081. PubMed ID: 34609506
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.
Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L
Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040
[TBL] [Abstract][Full Text] [Related]
7. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
Shen F; Yang CX; Lu Y; Zhang M; Tian RR; Dong XQ; Li AQ; Zheng YT; Pang W
J Med Virol; 2023 Feb; 95(2):e28516. PubMed ID: 36680413
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Booster Doses of the SARS-CoV-2 Inactivated Vaccine KCONVAC against the Mutant Strains.
Xiao C; Su J; Zhang C; Huang B; Mao L; Ren Z; Bai W; Li H; Lei G; Zheng J; Chen G; Liang X; Qiu C
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146822
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines.
Wang J; Huang L; Guo N; Yao YP; Zhang C; Xu R; Jiao YM; Li YQ; Song YR; Wang FS; Fan X
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112897
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune responses to inactivated COVID-19 vaccine up to 1 year in children with chronic hepatitis B infection.
Zhou Y; Chen Z; He Y; Peng X; Chang Y; Tan A; Li H; Cai D; Hu P; Chen M; Peng M; Xu H; Ren H
Front Cell Infect Microbiol; 2023; 13():1201101. PubMed ID: 37457966
[TBL] [Abstract][Full Text] [Related]
11. A longitudinal study of humoral immune responses induced by a 3-dose inactivated COVID-19 vaccine in an observational, prospective cohort.
Tao Y; Ma M; Hu F; Li M; Geng Y; Wan Y; Mao M; Chen L; Shen Y; Zhu L; Shen H; Chen Y
BMC Immunol; 2022 Nov; 23(1):57. PubMed ID: 36384440
[TBL] [Abstract][Full Text] [Related]
12. Stable and durable antibody responses in SARS-recovered donors vaccinated with inactivated SARS-CoV-2 vaccine.
Jia T; Wu Y; Liao G; Lei Y; Wu Z; Yang F; Chen J; Xie Q; Luo C; Chong Y; Luo H; Shu Y
J Med Virol; 2023 Mar; 95(3):e28662. PubMed ID: 36905115
[TBL] [Abstract][Full Text] [Related]
13. Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination.
Wang M; Zhou B; Fan Q; Zhou X; Liao X; Lin J; Ma Z; Dong J; Wang H; Ge X; Ju B; Zhang Z
Emerg Microbes Infect; 2023 Dec; 12(1):2151381. PubMed ID: 36444724
[TBL] [Abstract][Full Text] [Related]
14. Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: A prospective cohort study.
Wang H; Gan M; Wu B; Zeng R; Wang Z; Xu J; Li J; Zhang Y; Cao J; Chen L; Di D; Peng S; Lei J; Zhao Y; Song X; Yuan T; Zhou T; Liu Q; Yi J; Wang X; Cai H; Lei Y; Wen Y; Li W; Chen Q; Wang Y; Long P; Yuan Y; Wang C; Pan A; Wang Q; Gong R; Fan X; Wu T; Liu L
J Med Virol; 2023 Jan; 95(1):e28380. PubMed ID: 36478357
[TBL] [Abstract][Full Text] [Related]
15. Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization.
Chen C; Dai L; Zheng C; Li H; Li X; Yang M; Gao R; Yao J; Zhang Z; Shi Y; Han X
J Hematol Oncol; 2023 May; 16(1):47. PubMed ID: 37138279
[TBL] [Abstract][Full Text] [Related]
16. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
[TBL] [Abstract][Full Text] [Related]
17. What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?
Ravlić S; Kurtović T; Cvetko Krajinović L; Hećimović A; Miloš M; Mateljak Lukačević S; Markotić A; Halassy B
Hum Vaccin Immunother; 2023 Dec; 19(3):2270310. PubMed ID: 37905722
[TBL] [Abstract][Full Text] [Related]
18. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 vaccine in China.
Yan LN; Zhao ZX; Wang ZD; Xiao X; Liu PP; Zhang WK; Gu XL; Li B; Yu LP; Yu XJ
Expert Rev Vaccines; 2022 Oct; 21(10):1465-1473. PubMed ID: 35861138
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
